Protocol Library

Each card lists peptide research notes — vial size, example research dose range, reconstitution example, frequency example, cycle length example, and risk level. All entries are educational. Not medical advice.

Research use only. Educational content. Not medical advice, diagnosis, treatment, or a personal recommendation. Not intended for human consumption. Always discuss with a qualified healthcare professional.

CJC-1295 (no DAC)

low risk

Researched in growth hormone pulse research, often paired with GHRPs.

Vial: 2 mg
Dose: 100 mcg per use (research literature)
Freq: 1–3x daily (research example)
Cycle: 8–12 weeks (research example)

recoverymuscle-growthskin-hair

CJC-1295 with DAC

moderate risk

Researched in studies of sustained GH/IGF-1 elevation.

Vial: 2 mg
Dose: 1–2 mg weekly (research literature)
Freq: 1–2x weekly (research example)
Cycle: 8–12 weeks (research example)

muscle-growthrecoveryskin-hair

GHRP-2

moderate risk

Investigated for pulsatile growth hormone release via ghrelin receptor agonism.

Vial: 5 mg lyophilized vial
Dose: Commonly discussed research range: 100–300 mcg per administration.
Freq: 2–3x daily in research designs.
Cycle: 8–12 week educational example.

muscle-growthrecoveryperformance

GHRP-6

moderate risk

Investigated for GH pulsatility and appetite signaling via ghrelin receptor agonism.

Vial: 5 mg lyophilized vial
Dose: Commonly discussed research range: 100–300 mcg per administration.
Freq: 2–3x daily in research designs.
Cycle: 8–12 week educational example.

muscle-growthrecoveryperformance

IGF-1 DES

high risk

Investigated for local IGF-1 receptor activity with reduced IGFBP binding.

Vial: 1 mg lyophilized vial
Dose: Commonly discussed research range: 50–100 mcg per site.
Freq: Site-specific in research designs.
Cycle: 4 week educational example.

muscle-growthperformancerecovery

IGF-1 LR3

high risk

Studied for its role in IGF-1 pathway research, cellular growth signaling and muscle-research models.

Vial: 1 mg
Dose: Published research literature commonly cites 20–50 mcg per research day in cellular and animal study ranges.
Freq: Once daily in research scheduling examples.
Cycle: Short research cycles (commonly 4–6 weeks).

muscle-growthgrowth-factorrecovery

Ipamorelin

low risk

Researched as a selective ghrelin receptor agonist in GH studies.

Vial: 5 mg
Dose: 100–300 mcg per use (research literature)
Freq: 1–3x daily (research example)
Cycle: 8–12 weeks (research example)

recoverymuscle-growthskin-hair

PEG-MGF

moderate risk

Investigated for myogenic precursor activation via MGF/IGF-1Ec splice variant pathway.

Vial: 2 mg lyophilized vial
Dose: Commonly discussed research range: 200–400 mcg per administration.
Freq: 2–3x weekly in research designs.
Cycle: 4–6 week educational example.

muscle-growthrecoveryperformance

Sermorelin

low risk

Researched as a GHRH analog in pituitary GH release studies.

Vial: 5 mg
Dose: 100–300 mcg per use (research literature)
Freq: Nightly (research example)
Cycle: 8–12 weeks (research example)

recoverymuscle-growthsleep

Tesamorelin

moderate risk

Researched in studies of visceral adipose tissue.

Vial: 5 mg
Dose: 1–2 mg daily (research literature)
Freq: Once daily (research example)
Cycle: 12+ weeks (research example)

weight-managementmuscle-growth

Verified Research Supplier

Looking for a research supplier?

Enhanced Performance is a separate research supply platform. Visiting or purchasing is optional and not required to use PepToolbox.

Visit Enhanced Performance

Disclosure: Enhanced Performance is a separate platform connected to the owner of this website. Purchasing is optional and not required to use this tool.